Target discovery and validation in pancreatic cancer.
Pancreatic cancer is a lethal disease and rational strategies for early detection and targeted therapies are urgently required to alleviate the dismal prognosis of this neoplasm. The use of global RNA and protein expression-profiling technologies, such as DNA microarrays, serial analysis of gene expression, and mass spectrometric analysis of proteins, have led to identification of cellular targets with considerable potential for clinical application and patient care. These studies underscore the importance of pursuing large-scale profiling of human cancers not only for furthering our understanding of the pathogenesis of these malignancies but also for developing strategies to improve patient outcomes.
Beaty
Robert M
RM
Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Gronborg
Mads
M
Pollack
Jonathan R
JR
Maitra
Anirban
A
D015195:Drug Design; D020869:Gene Expression Profiling; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods; D020411:Oligonucleotide Array Sequence Analysis; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D040901:Proteomics / Q000379:methods*; D015203:Reproducibility of Results